ES2524369T3 - Unidad de dosificación que incluye un análogo de prostaglandina para el tratamiento del estreñimiento - Google Patents
Unidad de dosificación que incluye un análogo de prostaglandina para el tratamiento del estreñimiento Download PDFInfo
- Publication number
- ES2524369T3 ES2524369T3 ES10010211.0T ES10010211T ES2524369T3 ES 2524369 T3 ES2524369 T3 ES 2524369T3 ES 10010211 T ES10010211 T ES 10010211T ES 2524369 T3 ES2524369 T3 ES 2524369T3
- Authority
- ES
- Spain
- Prior art keywords
- constipation
- treatment
- prostaglandin analogue
- dosing unit
- analogue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010010774 Constipation Diseases 0.000 title abstract 2
- 150000003180 prostaglandins Chemical class 0.000 title abstract 2
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/23—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen containing rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyrane Compounds (AREA)
Abstract
Una unidad de dosificación para uso en el alivio o la prevención del estreñimiento en un paciente humano, que comprende un análogo de prostaglandina (PG) representado por la Fórmula (I) y/o sus tautómeros y un excipiente farmacéuticamente adecuado, donde la unidad de dosificación contiene dicho análogo de PG en una cantidad de aproximadamente 6-72 μg:**fórmula** donde A1 y A2 son los mismos o diferentes átomos de halógeno y B es -COOH, incluyendo sus sales, ésteres o amidas farmacéuticamente aceptables, y donde dicha unidad de dosificación es administrada suficientes veces al día como para que la dosis diaria total del análogo de PG sea de aproximadamente 48-72 μg.
Description
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33131601P | 2001-11-14 | 2001-11-14 | |
US331316P | 2001-11-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2524369T3 true ES2524369T3 (es) | 2014-12-05 |
Family
ID=23293447
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES02780083T Expired - Lifetime ES2368729T3 (es) | 2001-11-14 | 2002-11-14 | Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento del estreñimiento. |
ES10010211.0T Expired - Lifetime ES2524369T3 (es) | 2001-11-14 | 2002-11-14 | Unidad de dosificación que incluye un análogo de prostaglandina para el tratamiento del estreñimiento |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES02780083T Expired - Lifetime ES2368729T3 (es) | 2001-11-14 | 2002-11-14 | Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento del estreñimiento. |
Country Status (15)
Country | Link |
---|---|
US (3) | US8097653B2 (es) |
EP (2) | EP1443938B1 (es) |
JP (2) | JP4852229B2 (es) |
AR (3) | AR037524A1 (es) |
AT (1) | ATE522218T1 (es) |
BR (1) | BR0214075A (es) |
CA (1) | CA2464420C (es) |
CY (1) | CY1115856T1 (es) |
DK (2) | DK1443938T3 (es) |
ES (2) | ES2368729T3 (es) |
HK (1) | HK1155649A1 (es) |
LU (1) | LU92826I2 (es) |
PT (2) | PT2298314E (es) |
TW (1) | TWI331920B (es) |
WO (1) | WO2003041716A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI331920B (en) | 2001-11-14 | 2010-10-21 | Sucampo Ag | Unit dosage form for relieving or treating constipation in human patients |
JP4705782B2 (ja) * | 2002-10-23 | 2011-06-22 | スキャンポ・アーゲー | 肥満の処置のためのプロスタグランジン化合物 |
NZ541110A (en) * | 2002-12-27 | 2008-11-28 | Sucampo Ag | Derivatives of prostaglandins for treating abdominal discomfort |
JP5294559B2 (ja) * | 2003-07-03 | 2013-09-18 | スキャンポ・アーゲー | クロライドチャンネルオープナーとしてプロスタグランジンアナログを含む腸溶性組成物 |
TWI387454B (zh) * | 2004-09-02 | 2013-03-01 | Sucampo Ag | 治療胃腸道疾病之方法及組成物 |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
JP5241484B2 (ja) * | 2005-03-07 | 2013-07-17 | ザ ユニヴァーシティー オヴ シカゴ | 内皮細胞増殖及び内皮細胞遊走を減弱するためのオピオイドアンタゴニストの使用 |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US20060281818A1 (en) | 2005-03-21 | 2006-12-14 | Sucampo Ag, North Carolina State University | Method for treating mucosal disorders |
JP5711442B2 (ja) * | 2005-04-12 | 2015-04-30 | スキャンポ・アーゲーSucampo AG | 胃腸障害の処置のためのプロスタグランジン化合物およびプロトンポンプ阻害剤の併用 |
JP5265369B2 (ja) | 2006-01-24 | 2013-08-14 | 株式会社アールテック・ウエノ | 二環式化合物を含む医薬組成物およびその二環式化合物の安定化方法 |
MX2008009650A (es) * | 2006-01-24 | 2008-11-06 | R Tech Ueno Ltd | Formulacion de capsula de gelatina suave. |
US20090012165A1 (en) | 2007-07-03 | 2009-01-08 | Sucampo Ag | Pharmaceutical combination of nsaid and prostaglandin compound |
US20090030072A1 (en) * | 2007-07-03 | 2009-01-29 | Sucampo Ag | Pharmaceutical combination of opioid and prostaglandin compound |
RU2561873C2 (ru) * | 2009-09-18 | 2015-09-10 | Адолор Корпорейшн | Применение антагонистов опиоидных рецепторов при заболеваниях желудочно-кишечного тракта |
WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5350141A (en) * | 1976-10-18 | 1978-05-08 | Ono Pharmaceut Co Ltd | Stabilization of prostaglandin and prostaglandin analogues |
GB1581886A (en) | 1977-05-26 | 1980-12-31 | May & Baker Ltd | Prostanol derivatives |
JPH0681728B2 (ja) | 1987-10-02 | 1994-10-19 | 株式会社上野製薬応用研究所 | 下 剤 |
EP0310305B1 (en) * | 1987-10-02 | 1992-07-22 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Cathartics |
US5317032A (en) | 1987-10-02 | 1994-05-31 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Prostaglandin cathartic |
JP2579193B2 (ja) | 1988-07-19 | 1997-02-05 | 小野薬品工業株式会社 | 16,16−ジフルオロ−15−オキソ−15−デオキシpge誘導体 |
CA2027814C (en) | 1989-10-20 | 1996-07-30 | Ryuji Ueno | Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds |
CA2030345C (en) * | 1989-11-22 | 1998-12-08 | Ryuji Ueno | Use of 15-keto-prostaglandin compound for improvement of encephalic function |
CA2030346C (en) | 1989-11-22 | 2000-04-11 | Ryuji Ueno | Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds |
CA2030344C (en) | 1989-11-22 | 2000-04-18 | Ryuji Ueno | Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds |
EP0455448B1 (en) * | 1990-05-01 | 1998-12-09 | R-Tech Ueno Ltd. | Treatment of pancreatic disease with 15-keto-prostaglandin E compounds |
CA2046069C (en) | 1990-07-10 | 2002-04-09 | Ryuji Ueno | Treatment of inflammatory diseases with 15-keto-prostaglandin compounds |
JP2938579B2 (ja) | 1990-12-15 | 1999-08-23 | 株式会社上野製薬応用研究所 | 消化管壁保護剤 |
DE69213057T2 (de) * | 1991-03-14 | 1997-01-09 | Ueno Seiyaku Oyo Kenkyujo Kk | Stimulierung von Wundheilung mit 15-Keto-prostaglandinverbindungen |
DK0554794T3 (da) * | 1992-02-04 | 1999-04-26 | Eisai Co Ltd | Aminobenzoesyrederivater |
CA2150287C (en) * | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
JP3183615B2 (ja) * | 1994-06-03 | 2001-07-09 | 株式会社アールテック・ウエノ | 肝・胆道系疾患処置剤 |
JP3187438B2 (ja) * | 1996-06-10 | 2001-07-11 | 株式会社アールテック・ウエノ | エンドセリン拮抗剤 |
DE19717005A1 (de) * | 1997-04-23 | 1998-10-29 | Kennametal Inc | Spannfutter für Rundlaufwerkzeuge |
ATE401894T1 (de) | 1997-11-28 | 2008-08-15 | Sucampo Ag | Verwendung von 15-keto-prostaglandin-e verbindungen als endothelin antagonisten |
US6492417B1 (en) | 1997-12-22 | 2002-12-10 | Alcon Manufacturing, Ltd. | 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists |
HU230484B1 (hu) | 1999-10-15 | 2016-07-28 | Sucampo Ag | Egy biciklusos vegyületet és egy gliceridet tartalmazó új kompozíció |
NZ521784A (en) | 2000-04-06 | 2005-04-29 | Sucampo Ag | Bile secretion promoting composition |
US6414016B1 (en) * | 2000-09-05 | 2002-07-02 | Sucampo, A.G. | Anti-constipation composition |
TWI302100B (en) | 2001-05-02 | 2008-10-21 | Sucampo Ag | Composition for treating drug-induced constipation |
JP4597481B2 (ja) | 2001-05-18 | 2010-12-15 | スキャンポ・アーゲー | 下剤組成物 |
MXPA04002006A (es) | 2001-08-31 | 2004-06-07 | Sucampo Ag | Analogos de prostagladina como abridor del canal de cloruro. |
TWI331920B (en) | 2001-11-14 | 2010-10-21 | Sucampo Ag | Unit dosage form for relieving or treating constipation in human patients |
TWI263505B (en) | 2001-11-19 | 2006-10-11 | Sucampo Ag | Pharmaceutical composition comprising a C1C-2 channel opener |
NZ541110A (en) | 2002-12-27 | 2008-11-28 | Sucampo Ag | Derivatives of prostaglandins for treating abdominal discomfort |
-
2002
- 2002-11-13 TW TW091133227A patent/TWI331920B/zh not_active IP Right Cessation
- 2002-11-13 AR ARP020104349A patent/AR037524A1/es not_active Application Discontinuation
- 2002-11-14 BR BR0214075-6A patent/BR0214075A/pt not_active Application Discontinuation
- 2002-11-14 ES ES02780083T patent/ES2368729T3/es not_active Expired - Lifetime
- 2002-11-14 ES ES10010211.0T patent/ES2524369T3/es not_active Expired - Lifetime
- 2002-11-14 PT PT100102110T patent/PT2298314E/pt unknown
- 2002-11-14 WO PCT/JP2002/011862 patent/WO2003041716A1/en active Application Filing
- 2002-11-14 CA CA2464420A patent/CA2464420C/en not_active Expired - Lifetime
- 2002-11-14 US US10/293,516 patent/US8097653B2/en not_active Expired - Lifetime
- 2002-11-14 PT PT02780083T patent/PT1443938E/pt unknown
- 2002-11-14 DK DK02780083.8T patent/DK1443938T3/da active
- 2002-11-14 EP EP02780083A patent/EP1443938B1/en not_active Expired - Lifetime
- 2002-11-14 EP EP10010211.0A patent/EP2298314B1/en not_active Expired - Lifetime
- 2002-11-14 AT AT02780083T patent/ATE522218T1/de active
- 2002-11-14 DK DK10010211.0T patent/DK2298314T3/en active
- 2002-11-14 JP JP2003543603A patent/JP4852229B2/ja not_active Expired - Lifetime
-
2011
- 2011-05-25 JP JP2011117231A patent/JP2011201905A/ja active Pending
- 2011-09-21 HK HK11109944.5A patent/HK1155649A1/xx not_active IP Right Cessation
- 2011-12-20 US US13/330,942 patent/US8389542B2/en not_active Expired - Lifetime
-
2013
- 2013-01-30 US US13/754,138 patent/US20130143958A1/en not_active Abandoned
-
2014
- 2014-11-28 CY CY20141100997T patent/CY1115856T1/el unknown
- 2014-12-30 AR ARP140104956A patent/AR098997A2/es unknown
-
2015
- 2015-09-11 LU LU92826C patent/LU92826I2/xx unknown
-
2019
- 2019-03-21 AR ARP190100714A patent/AR117404A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2005513014A (ja) | 2005-05-12 |
JP4852229B2 (ja) | 2012-01-11 |
HK1155649A1 (en) | 2012-05-25 |
BR0214075A (pt) | 2004-09-28 |
US20120088824A1 (en) | 2012-04-12 |
DK2298314T3 (en) | 2014-12-01 |
EP1443938A1 (en) | 2004-08-11 |
US20130143958A1 (en) | 2013-06-06 |
US8097653B2 (en) | 2012-01-17 |
WO2003041716A1 (en) | 2003-05-22 |
US8389542B2 (en) | 2013-03-05 |
JP2011201905A (ja) | 2011-10-13 |
TW200300091A (en) | 2003-05-16 |
CY1115856T1 (el) | 2017-01-25 |
EP1443938B1 (en) | 2011-08-31 |
ATE522218T1 (de) | 2011-09-15 |
CA2464420C (en) | 2011-12-13 |
EP2298314A1 (en) | 2011-03-23 |
CA2464420A1 (en) | 2003-05-22 |
ES2368729T3 (es) | 2011-11-21 |
LU92826I2 (fr) | 2015-11-24 |
AR117404A2 (es) | 2021-08-04 |
US20030119898A1 (en) | 2003-06-26 |
DK1443938T3 (da) | 2011-09-26 |
PT2298314E (pt) | 2014-12-03 |
EP2298314B1 (en) | 2014-09-03 |
TWI331920B (en) | 2010-10-21 |
AR098997A2 (es) | 2016-06-22 |
AR037524A1 (es) | 2004-11-17 |
PT1443938E (pt) | 2011-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2524369T3 (es) | Unidad de dosificación que incluye un análogo de prostaglandina para el tratamiento del estreñimiento | |
PE20040134A1 (es) | Forma de dosificacion de una vez al dia de pramipexol | |
NO20055880L (no) | Memantin orale doseringsformer | |
CY1112260T1 (el) | Σκευασματα υδροκωδονης ελεγχομενης απελευθερωσης | |
AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
AR020001A1 (es) | COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO | |
ES2176436T3 (es) | Nueva forma de dosificacion farmaceutica oral. | |
AR004108A1 (es) | Uso del 4-(4-fluorobencilamino)-2-amino-1-etoxicarbonilaminobenceno y sus sales farmaceuticamente aceptables para la preparacion de un medicamento destinado a la profilaxis y el tratamiento de las consecuencias de la insuficiencia aguda y crónica de la irrigacion sanguinea cerebral y el tratamiento de las enfermedades neurodegenrativas | |
CY1111088T1 (el) | Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση | |
CO4340681A1 (es) | Procedimientos de uso para la inhibicion de la perdida osea y la disminucion del colesterol en suero | |
DE69225421D1 (de) | Sumatriptan enthaltende Arzneimittel | |
ES2093735T3 (es) | Derivados de melatonina para uso en la terapia de trastornos del sueño y en medicacion preanestesica. | |
WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
AR039335A1 (es) | Tableta de carga de droga alta | |
AR029174A1 (es) | Derivados de espirooxindol, proceso para su preparacion, formulacion farmaceutica, y utilizacion de los derivados en la manufactura de medicamentos | |
UY26977A1 (es) | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgésicos | |
MX9203444A (es) | Medicamentos. | |
CY1105120T1 (el) | Η αντιμετωπιση αναπνευστικων νοσων | |
AR045161A1 (es) | Derivados de quinazolina | |
CR9842A (es) | Composiciones de celecoxib | |
BR0313424A (pt) | Forma de dosagem e processo para a preparação de uma forma de dosagem | |
RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
ES2157005T3 (es) | Uso del acido boswellico y sus derivados para la inhibicion de la actividad normal y elevada de la elastasa de leucocitos o de la plasmina. | |
AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina |